North East and North Cumbria
ICS Formulary
 
back
8 Malignant disease and immunosuppression
08-03-04-03 Somatostatin analogues

Lanreotide
Formulary

  • Approved formulation include lanreotide 30mg long-acting injection and lanreotide 60mg, 90mg, and 120mg autogel injections.

    Existing patients 
    Green Traffic Light  for acromegaly, neuroendocrine tumour and carcinoid. 
    New patients (commenced treatment after July 2019)
    Red Traffic Light  for acromegaly, neuroendocrine tumour and carcinoid.


 
Link  LANREOTIDE AND OCTREOTIDE - Information for Treatment of Adults with acromegaly or neuroendocrine tumours in Primary Care

View adult BNF  View SPC online  View childrens BNF
Octreotide
Formulary

  • Approved formulations include octreotide 50microgram, 100microgram, and 500 microgram in 1ml, and 1mg in 5ml injections, and octreotide 10mg, 20mg and 30mg long-acting injections.
    Existing patients 
    Green Traffic Light  for acromegaly, neuroendocrine tumour and carcinoid. 
    New patients (commenced treatment after July 2019)
    Red Traffic Light  for acromegaly, neuroendocrine tumour and carcinoid.



  • Green Traffic Light Approved for the management of GI secretions in end of life care


 
Link  LANREOTIDE AND OCTREOTIDE - Information for Treatment of Adults with acromegaly or neuroendocrine tumours in Primary Care

View adult BNF  View SPC online  View childrens BNF
Pasireotide Signifor®
Formulary
  • Approved for the treatment of Cushing’s disease in line with NHS England Policy.
Link  Clinical Commissioning Policy: Pasireotide diaspartate: an injectable medical therapy for the treatment of Cushings’ Disease

Red View adult BNF  View SPC online  View childrens BNF  HCD